NCT00436254 2025-04-06
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
University of Washington
Phase 1 Completed
Clinical Trials
10 trialsNCT00803569 2023-10-04
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT01673217 2022-08-01
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT01536054 2020-03-27
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT02019524 2020-03-18
J65
San Antonio Military Medical Center
Phase 1 Completed
NCT00003002 2019-02-27
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
University of Washington
Phase 1 Completed
NCT00005023 2017-11-30
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
University of Washington
Phase 1 Completed
NCT02470559 2016-02-17
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT00023634 2015-03-06
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
SWOG Cancer Research Network
Phase 1 Terminated
NCT00091273 2014-06-20
Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
University of Virginia
Phase 1 Completed